Home / Lifestyle / Health & Fitness / Article /
Reliance-Backed Strand Life Sciences bags Indian patent for AI-powered blood test to detect cancer early
Updated On: 07 July, 2026 05:49 PM IST | Mumbai | mid-day online correspondent
The patented technology analyses cell-free DNA from a simple blood sample to identify early signs of cancer and predict its tissue of origin, offering hope for faster, more accessible and scalable screening

Reliance subsidiary develops AI-based blood test for early cancer detection (Pic/Special arrangement)
In a significant step towards advancing early cancer detection in India, Strand Life Sciences, a subsidiary of Reliance Industries Limited, has been granted an Indian patent for an integrated platform that uses artificial intelligence (AI) and cell-free DNA (cfDNA) analysis to detect cancer from a simple blood sample.
The patented technology combines high-quality genome sequencing, stringent quality control, methylation and fragmentomic analysis, and machine learning algorithms to identify early cancer-related changes in DNA circulating in the bloodstream. It can also predict the tissue of origin of the cancer, enabling doctors to investigate the affected organ at an earlier stage.


